Company*
(Country;
Symbol)

Company*
(Country;
Symbol)

Type/Product Area

Terms/Details (Date)

Alethia
Biotherapeutics
Inc.*

Emerillon
Therapeutics
Inc.*

Collaboration for a discovery and functional validation program to identify new drug candidates for treating bone-related diseases such as osteoporosis

Alethia will generate bone-specific cDNA libraries to help identify the genes (5/1)

Avantogen
Oncology Inc.
(PK:AVAOF)

SciClone Pharmaceuticals Inc. (SCLN)

Agreement assigning rights relating to pancreatic cancer product RP101 to SciClone

SciClone agreed to pay about $1.7M in up-front fees, plus success-based regulatory and commercial payments of up to $23.3M and royalties on any future sales (4/26)

AVI
BioPharma
Inc. (AVII)

Ercole Biotech Inc.*

Agreement to join the exon- skipping technology with the Splice Switching Oligonucleotide approach

The deal covers Duchenne muscular dystrophy and beta thalassemia; AVI is issuing common shares and Ercole will provide AVI with shares of its Series A-2 preferred stock (5/2)

Biolex
Therapeutics*

Genmab A/S (Denmark; CSE:GEN)

Agreement under which Genmab will evaluate Biolex's LEX System as a manufacturing platform for antibodies

The deal relates to Genmab's new UniBody antibody technology (5/7)

BioServe*

Seegene Inc.* (South Korea)

Partnership to develop and validate test systems for infectious diseases in the Indian market

Seegene will access BioServe's repository of Indian DNA samples to collaborate on developing test systems for illnesses such as sexually transmitted diseases, tuberculosis and HIV; BioServe will offer diagnostic testing services using Seegene's Seeplex STD detection system (5/14)

Celera
Genomics
Group (NYSE:CRA)

Laboratory Corp. of America (NYSE:LH)

Licensing agreement to Celera's breast cancer metastasis and estrogen/ progesterone receptor discoveries

LabCorp can select from Celera's findings to develop and commercialize two molecular oncology laboratory service tests (4/25)

Cepheid Inc.
(CPHD)

Instrumentation Laboratory*

Exclusive agreement to develop a line of hemostasis tests to be used on Cepheid's GeneXpert System

Instrumentation Laboratory will market the system; the first tests will allow hospital and independent clinical laboratories to detect Factor II G202210A and Factor V Leiden genetic variations associated with increased risk of blood clots (4/24)

Chembio
Diagnostics
Inc. (OTC BB:
CEMI)

Avago Technologies Inc.*

Collaboration to integrate Chembio's DPP technology and assay development expertise with Avago's opto- electronic measurement technology

The parties intend to develop rapid point- of- are diagnostic systems, with the first focus on various HIV test prototypes (5/8)

CollaGenex
Pharmaceuticals
Inc. (CGPI)

QuatRx Pharmaceuticals Co. (QTRX)

Licensing agreement to develop and commercialize becocalcidiol, a vitamin D analogue in Phase II trials for the topical treatment of mild to moderate psoriasis

CollaGenex will pay an up-front fee of $1.5M and will be responsible for all further development costs; QuatRx also may re- ceive milestone payments and royalties (5/16)

CyDex Inc.*

Proteolix Inc.*

Licensing agreement for the Captisol technology

Proteolix will use the technology with a proteasome inhibitor, PR-171, which has shown promise in treating multiple myeloma and mantle cell lymphoma (5/1)

CyDex Inc.*

Sunesis Pharmaceuticals Inc. (SNSS)

Licensing agreement for its Captisol enabling technology for formulation of a selective Aurora kinase inhibitor with potent anti-tumor activity across a number of nonclinical human cancer models

CyDex granted Sunesis global rights to Captisol for a formulation of SNS-314 (5/3)

CytoGenix Inc.
(OTC BB:CYGX)

Eurogentec SA* (Belgium)

Companies executed a letter of intent to collaborate on syn-DNA development

They plan to optimize manufacturing and to implement purification and quality-control parameters (5/10)

DeveloGen AG*
(Germany)

Andromeda* (Israel)

Agreement for DeveloGen to sell its Type I diabetes therapy DiaPep277 to Andromeda

The product is a Phase III drug; DeveloGen will receive regulatory and commercial milestones, as well as royalties on eventualsales (4/18)**

DiagnoCure
Inc. (Canada;
TSX:CUR)

Targeted Diagnostics & Therapeutics Inc.*

Exclusive worldwide rights agreement to two molecular tests for colorectal cancer and an option to a CLIA- certified U.S. service laboratory to commercialize molecular cancer diagnostics tests

TDT gets an initial payment of $2.2M in DiagnoCure shares, and is entitled to milestone and royalty payments (5/1)

Diosynth
Biotechnology*

VGX Pharmaceuticals Inc.*

Agreement for process development activities and cGMP production of clinical trial material for VGX's VGX-100

Terms were not disclosed (5/2)

Entelos Inc.
(LSE:ENTL)

Jubilant Organosys (India; NSE:JUBILANT)

Strategic alliance to jointly develop and provide drug discovery and development services, including predictive biosimulation, preclinical and clinical testing, drug formulation, manufacturing and supply

The companies also plan to build a portfolio of drug candidates together (5/8)

Epigenomics
AG (Germany;
FSE:ECX)

Myriad Genetics Inc. (MYGN)

Collaboration to identify DNA methylation biomarkers that may predict patient response to an undisclosed marketed oncology drug

Myriad will provide patient samples for profiling in Epigenomics' Differential Methylation Hybridization microarray platform and OncoSign technology (5/9)

Expression
Pathology Inc.*

Oridis Biomed GmbH* (Austria)

Alliance to offer tissue microproteomic capabilities for protein biomarker discovery and validation

The relationship combines Expression's Liquid Tissue and Director technologies with Oridis' Tissomics platform for high- throughput analysis of patient tissue and its access to tissue samples; the goal is to be able to identify and measure protein biomarkers that relate to specific disease progression, drug response and toxicity (5/4)

Gene Logic Inc.
(GLGC)

Abbott Laboratories (NYSE:ABT)

Agreement to use Gene Logic's repositioning technology to seek additional development paths for multiple Abbott drug candidates that have passed Phase I trials

Gene Logic is entitled to milestone payments for each drug candidate Abbott returns to clinical development; it also may receive royalties, and it has the option to license any candidate that Abbott does not pursue, in which case Abbott would receive milestone and royalty payments (5/10)

Genentech
Inc. (NYSE:DNA)

Sangamo BioSciences Inc. (SGMO)

Agreement granting Genentech rights to use Sangamo's zinc finger DNA-binding protein technology to enhance protein production

Sangamo will be entitled to an up-front fee, an ongoing technology access fee and potential milestone payments (4/30)

Gen-Probe Inc.
(GPRO)

3M (NYSE:MMM)

Exclusive, worldwide collaboration to develop and commercialize rapid, easy-to-use nucleic acid tests to detect certain health care-associated infections, such as methicillin- resistant Staphylococcus aureus

Gen-Probe will be responsible for assay development, which 3M largely will fund; 3M will manage clinical trials and regulatory affairs, and will handle global sales and marketing, with co-promotion assistance from Gen- robe, which is entitled to milestone payments and a share of resulting profits (5/1)

ICeutica Inc.*

Nordic Biotech* (Denmark)

Agreement to establish a new company known as Spree Pharma A/S

It enables Spree to leverage iCeutica's Encapsulated Organic Nanoparticle platform to reformulate a number of compounds for launch and marketing (5/9)

Inno Biologics
Sdn. Bhd.*
(Malaysia)

Avesta Biotherapeutics & Research Pvt. Ltd. (India)

Five-year development and manufacturing contract for several of Avesta's pipeline molecules

Inno will provide pilot, clinical- or commercial-scale production for the molecules (5/10)

IsoTis Inc.
(PK:ISTSF)

OctoPlus NV (the Netherlands; AMSTERDAM:OCTO)

Agreement for rights to the PolyActive technology

IsoTis received an up-front payment of $1.7M and future royalty payments; it retains the rights to manufacture, market and sell orthopedic plugs and cement restrictors based on the technology (4/25)

Millenium
Biologix Corp.
(Canada; TSX:MBC)

Medtronic of Canada Ltd. (unit of Medtronic Inc.; NYSE:MDT)

Agreement for the sale of MBC's resorbable synthetic bone graft technology, Skelite and Warsaw Orthopedic Inc.*

Millenium will receive an undisclosed payment and potential milestone and contingent payments (5/1)

Monogram
Biosciences
Inc. (MGRM)

Caliper Life Sciences (CALP)

Licensing agreement for Monogram's microfluidics patent portfolio on an exclusive basis

Financial terms were not disclosed (5/3)

Nabi Bio-
pharmaceuticals
(NABI)

Bioniche Teoranta (Ireland; unit of Bioniche Life Sciences Inc.; TSX:BNC)

Agreement for Nabi to sell its Aloprim (allopurinol sodium) for injection product to Bioniche

Nabi will receive $3.7M in the deal: $1.3M at closing, $1.4M at the end of 2007 and $1M at the end of 2008 (4/20)

New England
Biolabs*

Integrated Genomics*

Licensing agreement for the ERGO bioinformatics software developed and maintained by Integrated Genomics

New England Biolabs will use the genome- analysis tools for gene annotation, metabolic reconstruction and enzyme data-mining, as well as for comparative genomic purposes(5/14)

NovaThera
Ltd.* (UK)

Gamida Cell Ltd.* (Israel)

Partnership to pool technology and expertise with the clinical team at Papworth Hospital to develop cell therapeutics for lung repair and regeneration

The team will clinically test populations of cord blood-derived stem cells expanded by Gamida's technologies and produced using NovaThera's bioprocessor technology for the manufacture of stem cells (5/9)

NuGEN
Technologies
Inc.*

bioMerieux (France; PARIS:BIM)

Deal to cross-license intellectual property, as well as a supply agreement for NuGEN's WT-Ovation RNA Amplification System

The deal gives bioMerieux nonexclusive rights to specific NuGEN amplification technologies; NuGEN gained access to bioMerieux linear amplification technologies using chimeric primers (5/9)

Pro- Pharmaceuticals Inc. (AMEX:PRW)

Digna Biotech SL* (Spain)

Agreement under which Pro- pharmaceuticals will apply its carbohydrate technology platform in combination with Digna drugs for chronic hepatitis C infection

They will evaluate the ability of carbohydrate compounds, starting with Davanat, to improve the delivery of Digna's drugs (4/30)

Proteome
Sciences plc
(UK; LSE:PRM)

Onconome Inc.*

Agreement to use Proteome's Proteoshop proteomics technology to analyze and validate prostate and colon cancer biomarkers

Proteome also will undertake new bio- marker discovery using material supplied by Onconome (4/25)**

Proteome
Systems Ltd.
(Australia;
ASX:PXL)

Minerva Healthcare Inc. (venture launched by Impax Laboratories Inc., Athena Diagnostics Inc. and IVAX Corp.)

Licensing and commercialization deal for Proteome's Eukarion topical compounds

PSL has granted an option to license its topical Eukarion compounds to Minerva for development and commercialization; PSL will receive an up-front license fee of $4M, along with an undisclosed milestone payment for clinical development, 12% royalties on sales and a 10% equity stake in Minerva (5/7)

Quest
PharmaTech
Inc. (Canada;
CDNX:QPT)

Paramount BioSciences LLC*

Paramount acquired multinational rights to Quest's SonoLight technology for dermatology applications

The deal gives Paramount access to a library of Hypocrellin B-derived photo- sensitizers that are activated by light or ultrasound energy sources; Quest will receive an up-front payment and be eligible for milestones in excess of $35M, plus royalties on product sales (5/14)